Literature DB >> 18284511

The efficacy of '0.05% Clobetasol + 2.5% zinc sulphate' cream vs. '0.05% Clobetasol alone' cream in the treatment of the chronic hand eczema: a double-blind study.

G Faghihi1, F Iraji, A Shahingohar, Ah Saidat.   

Abstract

BACKGROUND: Many therapeutic modalities have been suggested for treatment of the chronic hand eczema. Despite good immediate efficacy of some of these treatments, there is high recurrence of the dermatitis following cessation of the treatment. AIM: Regarding the beneficial effects of the zinc sulfate on the skin, we designed a double blind study to evaluate the efficacy of the '0.05% Clobetasol + 2.5% zinc sulphate' cream versus '0.05% Clobetasol alone' cream in the treatment of the chronic hand eczema. SUBJECTS AND METHODS: This study was a double-blind, right to left, prospective, clinical trial. In total, 47 patients with chronic hand eczema admitted to dermatology center of Isfahan University of Medical Sciences were selected and their right hand or left hand were selected at random to be treated with either the '0.05% Clobetasol + 2.5% zinc sulphate' cream or '0.05% Clobetasol alone' cream twice daily for 2 weeks. All of the patients were treated for 2 weeks and were followed up at weeks 2, 4, 6 and 8 after starting the treatment. For determining the severity of chronic hand eczema, we assessed and scored 4 different characteristics of the lesions including redness; scaling; lichenification and pruritus. The data were analyzed using SPSS program (release 13) and statistical tests including Mann-Whitney test.
RESULTS: Overall, 47 patients (94 samples) were evaluated. All of these patients had similar and symmetrical lesions on their right and left hands. Out of them, 35 patients were females and 12 patients were male. In all of the evaluated characterisitics, the '0.05% Clobetasol + 2.5% zinc sulphate' cream was more effective than '0.05% Clobetasol alone' cream (P < 0.05). The recurrence rate of eczema was significantly lower in the group treated with this combination treatment (P < 0.05).
CONCLUSION: With regard to the encouraging results of the combination treatment with Clobetasol + zinc sulphate, we suggest that in a more extensive clinical trial, the efficacy of this treatment against chronic hand dermatitis be evaluated. In addition, evaluation of this combination therapy against other inflammatory dermatosis seems to be logical.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284511     DOI: 10.1111/j.1468-3083.2007.02533.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema.

Authors:  Justin J Gandy; Jacques R Snyman; Constance Ej van Rensburg
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-09-08

2.  Interventions for hand eczema.

Authors:  Wietske Andrea Christoffers; Pieter-Jan Coenraads; Åke Svensson; Thomas L Diepgen; Janine L Dickinson-Blok; Jun Xia; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-04-26

Review 3.  Zinc therapy in dermatology: a review.

Authors:  Mrinal Gupta; Vikram K Mahajan; Karaninder S Mehta; Pushpinder S Chauhan
Journal:  Dermatol Res Pract       Date:  2014-07-10

Review 4.  Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach.

Authors:  Anupam Das; Saumya Panda
Journal:  Indian J Dermatol       Date:  2017 May-Jun       Impact factor: 1.494

Review 5.  Bioactive Compounds for Skin Health: A Review.

Authors:  Monika Michalak; Monika Pierzak; Beata Kręcisz; Edyta Suliga
Journal:  Nutrients       Date:  2021-01-12       Impact factor: 5.717

6.  Topical 0.05% clobetasol cream in the treatment of chronic hand eczema: A protocol for systematic review and meta-analysis.

Authors:  Mingyi Jing; Qianying Yu; Baohua Zhu; Fan Yuan; Jie Zhang; Li Peng; Wenxia Lin; Mingling Chen
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.